Patents by Inventor Jonathan DEANE

Jonathan DEANE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for potentiating immune activity
    Patent number: 12551555
    Abstract: The present disclosure provides compositions and methods for enhancing immunity (or immune response). The compositions and methods are particularly useful for potentiating immune response of a lymphoid cell. The compositions and methods are also applicable for treating cancer and other diseases.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: February 17, 2026
    Assignee: Kumquat Biosciences Inc.
    Inventors: Yi Liu, Jonathan Deane, Amy Strasner, Liansheng Li, Matthew R. Janes, Karen K. Wong, Pingda Ren
  • HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF
    Publication number: 20240398828
    Abstract: The present disclosure provides compounds and pharmaceutical compositions comprising the same. The compounds, pharmaceutical compositions thereof, and methods of using the same have a range of utilities as therapeutics, diagnostics, and research tools. The subject compositions and methods are particularly useful for potentiating immune response and/or applicable for treating cancer and other diseases.
    Type: Application
    Filed: May 20, 2024
    Publication date: December 5, 2024
    Inventors: Liansheng Li, Xiuwen Zhu, Pingda Ren, Jonathan Deane, Lomon So, Yi Liu
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
    Publication number: 20240376099
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Application
    Filed: May 30, 2024
    Publication date: November 14, 2024
    Inventors: Phillip ALPER, Jonathan DEANE, Songchun JIANG, Tao JIANG, Thomas KNOEPFEL, Pierre-Yves MICHELLYS, Daniel MUTNICK, Wei PEI, Peter SYKA, Guobao ZHANG, Yi ZHANG
  • Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
    Patent number: 12006354
    Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and producibility over recombinant human IL2 formulations such as Proleukin®.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: June 11, 2024
    Assignee: NOVARTIS AG
    Inventors: Jonathan Deane, Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Glen Spraggon
  • HETEROCYCLES AND USES THEREOF
    Publication number: 20240166641
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: September 7, 2023
    Publication date: May 23, 2024
    Inventors: Liansheng Li, Xiuwen Zhu, Pingda Ren, Jonathan Deane, Lomon So, Yi Liu
  • ANTIBODY-CYTOKINS ENGRAFTED PROTEINS AND METHODS OF US IN THE TREATMENT OF CANCER
    Publication number: 20240141022
    Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and produceability over recombinant human IL2 formulations such as Proleukin®.
    Type: Application
    Filed: December 26, 2023
    Publication date: May 2, 2024
    Inventors: Jonathan DEANE, Yaiza DIAZ-DE-DURANA, Michael DIDONATO, Christophe FILIPPI, Glen SPRAGGON
  • COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE
    Publication number: 20230092294
    Abstract: The present disclosure provides compositions and methods for enhancing immunity (or immune response). The compositions and methods are particularly useful for potentiating immune response of a lymphoid cell. The compositions and methods are applicable for treating cancer and other diseases.
    Type: Application
    Filed: June 10, 2022
    Publication date: March 23, 2023
    Inventors: Yi Liu, Jonathan Deane, Amy Strasner, Matthew R. Janes, Liansheng Li, Karen K. Wong, Pingda Ren
  • DC-SIGN ANTIBODY DRUG CONJUGATES
    Publication number: 20230053449
    Abstract: Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 23, 2023
    Inventors: Lisa BARNETT, Steven BENDER, Alex Cortez, Sarah COX, Jonathan DEANE, Scott Martin GLASER, Ben WEN, Tom Yao-Hsiang WU
  • COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY
    Publication number: 20230044323
    Abstract: The present disclosure provides compositions and methods for enhancing immunity (or immune response). The compositions and methods are particularly useful for potentiating immune response of a lymphoid cell. The compositions and methods are also applicable for treating cancer and other diseases.
    Type: Application
    Filed: June 10, 2022
    Publication date: February 9, 2023
    Inventors: Yi Liu, Jonathan Deane, Amy Strasner, Liansheng Li, Matthew R. Janes, Karen K. Wong, Pingda Ren
  • DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS
    Publication number: 20210170043
    Abstract: Provided herein are immunoconjugates comprising an anti-DC-SIGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.
    Type: Application
    Filed: October 30, 2019
    Publication date: June 10, 2021
    Inventors: Lisa BARNETT, Steven BENDER, Charles Y. CHO, Sarah COX, Jonathan Deane, Scott Martin GLASER, Xueshi Hao, Shailaja KASIBHATLA, Weijia OU, Tetsuo UNO, Yongqin WAN, Ben WEN, Tom Yao-Hsiang WU
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
    Publication number: 20210101902
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 8, 2021
    Inventors: Phillip ALPER, Jonathan DEANE, Songchun JIANG, Tao JIANG, Thomas KNOEPFEL, Pierre-Yves MICHELLYS, Daniel MUTNICK, Wei PEI, Peter SYKA, Guobao ZHANG, Yi ZHANG
  • Compounds and compositions as inhibitors of endosomal toll-like receptors
    Patent number: 10954233
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: March 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Phillip Alper, Jonathan Deane, Songchun Jiang, Tao Jiang, Thomas Knoepfel, Pierre-Yves Michellys, Daniel Mutnick, Wei Pei, Peter Syka, Guobao Zhang, Yi Zhang
  • ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE IN THE TREATMENT OF CANCER
    Publication number: 20200270334
    Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and produceability over recombinant human IL2 formulations such as Proleukin®.
    Type: Application
    Filed: May 22, 2018
    Publication date: August 27, 2020
    Inventors: Jonathan Deane, Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Glen Spraggon
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
    Publication number: 20190211009
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Application
    Filed: September 6, 2017
    Publication date: July 11, 2019
    Inventors: Phillip Alper, Jonathan DEANE, Songchun JIANG, Tao JIANG, Thomas KNOEPFEL, Pierre-Yves MICHELLYS, Daniel MUTNICK, Wei PEI, Peter SYKA, Guobao ZHANG, YI ZHANG